43 completed. 43 Phase 2, 17 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 43 |
| Phase 1 | 17 | Completed 17 |
| Phase 3 | 3 | Completed 3 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration Iptacopan (LNP023), Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | Novartis Pharmaceuticals | 168 | 2022-02-17 | 2026-10-27 |
| Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE] Gene Therapy Product-MCO-010, Sham Injection - Retinitis Pigmentosa, Retinitis | Phase 2 | Completed | Nanoscope Therapeutics Inc. | 27 | 2021-07-13 | 2024-03-22 |
| Patient-centered Modular CBT for CPTSD: A Randomised Controlled Pilot Study Psychotherapy - Complex Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | Danish Veterans Centre | 60 | 2021-01-05 | 2025-04-02 |
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome NPI-001, Placebo - Usher Syndromes | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 49 | 2020-09-03 | 2026-07-01 |
| ADVM-022 Intravitreal Gene Therapy for DME 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Completed | Adverum Biotechnologies, Inc. | 36 | 2020-05-28 | 2025-07-10 |
| Gene Therapy for Achromatopsia (CNGA3) adeno-associated virus vector AAV- CNGA3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 11 | 2019-08-12 | 2022-12-01 |
| Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema LKA651, Lucentis - Diabetic Macular Edema | Phase 2 | Completed | Novartis Pharmaceuticals | 91 | 2019-05-24 | 2024-06-20 |
| Acute Treatment Trial in Adult Subjects With Migraines Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System - Migraine | Phase 2 / Phase 3 | Completed | Pfizer | 2154 | 2019-03-25 | 2023-09-25 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome Sodium Valproate 200Mg E/C Tablet, Sodium Valproate matched placebo - Wolfram Syndrome | Phase 2 | Completed | University of Birmingham | 63 | 2018-12-28 | 2026-05-05 |
| Side Effects of Atropine (SEA) Study 0.01% concentration atropine drops - Myopia | Phase 1 / Phase 2 | Completed | Jeffrey J. Walline, OD PhD | 31 | 2018-07-23 | 2022-12-02 |
| Gene Therapy for Achromatopsia (CNGB3) AAV - CNGB3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 23 | 2017-01-16 | 2023-03-08 |
| A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 21 | 2017-01-01 | 2024-03-13 |
| Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. AZD4017, Placebo - Idiopathic Intracranial Hypertension | Phase 2 | Completed | University of Birmingham | 31 | 2014-04-25 | 2021-10-27 |
| Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine ELS-M11, Placebo - Migraine Headaches | Phase 1 / Phase 2 | Completed | Achelios Therapeutics | 48 | 2014-03-01 | 2017-07-11 |
| Nitisinone for Type 1B Oculocutaneous Albinism Nitisinone - Albinism, Vision Loss | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2013-04-16 | 2019-02-26 |
| Revacept in Symptomatic Carotid Stenosis Revacept, Placebo - Carotid Stenosis, Atherosclerosis | Phase 2 | Completed | AdvanceCor GmbH | 158 | 2013-03-08 | 2021-01-28 |
| Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study verum tDCS, sham tDCS, VRT - Hemianopia, Stroke | Phase 1 / Phase 2 | Completed | University of Magdeburg | 19 | 2013-03-01 | 2016-03-09 |
| Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study tDCS, Standard rehabilitation - Hemianopia, Stroke | Phase 1 / Phase 2 | Completed | University of Magdeburg | 14 | 2013-01-01 | 2016-10-17 |
| CNTF Implants for CNGB3 Achromatopsia NT-501 CNTF-releasing implant - Eye Disease, Achromatopsia | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2012-07-01 | 2016-11-21 |
Showing 20 of 43. Sign in to see all of them.
Blindness (8) · Amblyopia (5) · Color Vision Defects (5) · Macular Degeneration (5) · Eye Diseases (4) · Hemianopsia (4) · Photophobia (4) · Stroke (4) · Geographic Atrophy (3) · Retinal Diseases (3) · Retinitis Pigmentosa (3) · Usher Syndromes (3) · Vision, Low (3) · Wet Macular Degeneration (3)
Nervous System Diseases (43) · Neurologic Manifestations (43) · Sensation Disorders (43) · Pathological Conditions, Signs and Symptoms (42) · Signs and Symptoms (42) · Eye Diseases (39) · Brain Diseases (15) · Central Nervous System Diseases (15) · Blindness (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Eye Diseases, Hereditary (10) · Ear Diseases (9) · Genetic Diseases, Inborn (9) · Hearing Disorders (9)
Ranibizumab (4) · salicylhydroxamic acid (3) · nitisinone (2) · 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid (1) · Acetaminophen (1) · Acetazolamide (1) · Aspirin (1) · Atropine (1) · Calcium Dobesilate (1) · Ciliary Neurotrophic Factor (1) · Codeine (1) · Control Groups (1) · Dantrolene (1) · Dexamethasone (1) · Electroconvulsive Therapy (1)
Novartis Pharmaceuticals (4) · University of Magdeburg (4) · US Department of Veterans Affairs (3) · MeiraGTx UK II Ltd (2) · National Eye Institute (NEI) (2) · Shahid Beheshti University of Medical Sciences (2) · University of Birmingham (2) · Achelios Therapeutics (1) · AdvanceCor GmbH (1) · Adverum Biotechnologies, Inc. (1) · Asalus Medical Instruments Limited (1) · Danish Veterans Centre (1) · Jaeb Center for Health Research (1) · Jeffrey J. Walline, OD PhD (1) · Karolinska Institutet (1)
United States (26) · United Kingdom (8) · Germany (6) · Canada (4) · Puerto Rico (4) · Spain (3) · Austria (2) · France (2) · Iran (2) · Australia (1) · China (1) · Denmark (1) · Poland (1) · Sweden (1) · Turkey (Türkiye) (1)
Nancy Rocheleau, Program Analyst (3) · John Fryer, Ph.D., Asst. Director (2) · Agnes Wong, MD (1) · Alan Lankford, PhD (1) · Alan R. Spitzer, MD (1) · Alexander Foss, BA BMBCh MRCP MRCOphth FRC (1) · Alexandra Sinclair, MbChb PhD (1) · Barbara J. Stoll, MD (1) · Bernhard A Sabel, Ph.D. (1) · Bernhard A Sabel, Prof. Dr. (1) · Beverly S. Brozanski, MD (1) · Brian P Brooks, M.D. (1) · Charles C. Barr, MD (1) · Craig A Elmets (1)
PMID 37314061, PMID 10654946, PMID 20212198, PMID 20837811, PMID 23688108, PMID 24504128, PMID 24756302, PMID 24756514, PMID 24781936, PMID 25205868, PMID 25370510, PMID 25370513, PMID 25678831, PMID 26024112, PMID 26335066, PMID 26618282, PMID 26778344, PMID 26934136, PMID 26951772, PMID 27694262, PMID 27978569, PMID 28082176, PMID 28130349, PMID 28492874, PMID 28923789, PMID 29800250, PMID 30674731, PMID 31215818, PMID 31592954, PMID 33098644, PMID 34185708, PMID 34219679, PMID 35129211, PMID 35695006, PMID 36240084, PMID 37172884, PMID 37418643, PMID 37740611, PMID 40010822
2018 (2), 2009 (1), 2016 (1), M01RR000054 (1), M01RR000070 (1), R21DK113487 (1), U10EY011751 (1), U10EY017281 (1), U10EY017387 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1)